Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni

Biogen Inc (NASDAQ: BIIB) will miss quarterly sales expectations for its Tecfidera treatment for multiple sclerosis Friday but the ...